Laura Periman
Ophthalmology · Seattle, WANPI 1376755009
Payments from drug & device makers
Across 1,659 payments — averaging $1171.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$349K
- Mallinckrodt Hospital Products Inc.$273K
- Tarsus Pharmaceuticals, Inc.$182K
- Bausch & Lomb Americas Inc.$168K
- Oyster Point Pharma, Inc.$159K
- Sun Pharmaceutical Industries Inc.$147K
- plus $667K from 35 others
Across 5 payments — averaging $4548.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch Health US, LLC$14K
- Novartis$7K
- Oyster Point Pharma, Inc.$2K
What the payments were for
- Consulting fees$420,30925%
- Speaking & faculty fees$1,097,36466%
- Travel & lodging$99,7946%
- Food & beverage$39,9722%
- Education$9,9751%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTHAR$270,343
- CEQUA$144,026
- XDEMVY$131,254
- RESTASIS$116,493
- XIIDRA$111,166
- MIEBO$110,287
- TYRVAYA$99,948
- VUITY$95,684
- RESTASIS MULTIDOSE$66,419
- TRYPTYR$65,965
- M22$49,397
- optilight$38,873
- Systane$33,950
- ILUX$29,686
- EYSUVIS$23,342
- TearCare$18,560
- Lumenis Pulse 120H$17,762
- BLINK NUTRITEARS$15,300
- TEPEZZA$12,477
- DURYSTA$12,094
How this compares
$1,944,276 in reported general payments places this provider in the 95th percentile of 428 ophthalmology providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XdemvyLotilaner | 36 | $65,137 |
| MieboPerfluorohexyloctane/Pf | 24 | $18,030 |
| XiidraLifitegrast | 11 | $16,809 |
| TyrvayaVarenicline Tartrate | 15 | $9,523 |
| Loteprednol Etabonate | 11 | $508 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Tarsus Pharmaceuticals, Inc.Xdemvy | $181,747 | $65,13736 claims |
| Bausch & Lomb Americas Inc.Miebo, Xiidra | $167,685 | $34,83835 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $158,999 | $9,52315 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $1,171 | $50811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 428 ophthalmology providers in Washington.
Other ophthalmology in Seattle
- Sheldon CowenSeattle$560K
- Raghu MudumbaiSeattle$284K
- Jennifer ChaoSeattle$212K
- Kathryn PeppleSeattle$143K
- Debarshi MustafiSeattle$85K
- Michelle CabreraSeattle$75K
- Paul GriggsSeattle$62K
- Aaron KuzinSeattle$59K
- Lisa Olmos de KooSeattle$50K
- Bruce CameronSeattle$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.